Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor
暂无分享,去创建一个
M. Gasparetto | N. Croft | I. Sanderson | S. Naik | P. Deb | A. Kadir | N. Burgess | Protima Deb | D. Studart
[1] R. Battat,et al. Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data. , 2021, The American journal of gastroenterology.
[2] M. Dubinsky,et al. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease , 2021, The American journal of gastroenterology.
[3] H. Peeters,et al. Ultra-proactive therapeutic drug monitoring of infliximab based on point-of-care-testing in inflammatory bowel disease: results of a pragmatic trial. , 2021, Journal of Crohn's & colitis.
[4] Inge Christoffer Olsen,et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. , 2021, JAMA.
[5] J. Feuerstein,et al. Highs and Lows of Proactive Therapeutic Drug Monitoring in Crohn’s Patients , 2021, Digestive Diseases and Sciences.
[6] A. Ananthakrishnan,et al. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study , 2020, Digestive Diseases and Sciences.
[7] A. Griffiths,et al. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. , 2020, Journal of Crohn's & colitis.
[8] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.
[9] B. Weiss,et al. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn's Disease Compared with Reactive Monitoring. , 2019, Gastroenterology.
[10] B. Vaughn,et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. , 2019, Journal of Crohn's & colitis.
[11] M. Parkes,et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.
[12] A. Griffiths,et al. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis , 2018, Journal of Crohn's & colitis.
[13] A. Gasbarrini,et al. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study , 2018, Journal of Crohn's & colitis.
[14] Ravy K. Vajravelu,et al. Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] Siddharth Singh,et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.
[16] M. Silverberg,et al. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.
[17] K. Van Steen,et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.
[18] W. Sandborn,et al. Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study , 2014, Inflammatory bowel diseases.
[19] L. A. Christensen,et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.